[Genetic engineering approaches to the study of insulin-dependent diabetes mellitus markers]

Voprosy Meditsinskoi Khimii
|January 31, 1998
PubMed

In the present study, gene-engineering producers for proinsulin and peptide fragments of glutamic acid decarboxylase (GAD), the main autoantigens of islet cells responsible for development of insulin-dependent diabetes mellitus (IDDM), were prepared. Basing on the obtained antigens. ELISA was developed to determine the autoantibodies in sera of patients. Sera from the following two groups of IDDM patients were studied: 1) adult patients with recently developed IDDM before insulinotherapy, and 2) adult patients with long-lasting IDDM with associated complications. Insulin/proinsulin antibodies were detected in 20% patients of group 1 and 41.7% patients of group 2. In sera from IDDM patients, antibodies to two GAD fragments containing amino acid sequences 1-80 and 151-585 were also detected. 16% of sera from patients with recently developed IDDM and 37.5% of sera from patients with long-lasting IDDM reacted with N-terminal GAD fragment. 12% of sera from group 1 and 45.8% of sera from group 2 reacted with central-C-terminal GAD fragment. The rate of sera of IDDM patients with detected antibodies in this study was some lower than that described in the literature.

Related Concept Videos

What is Genetic Engineering?00:49

What is Genetic Engineering?

Overview
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...